is allulose a glp-1 agonist Secretion of but not GIP potently stimulated by luminal d-Allulose (d-Psicose) in rats Evolution of GLP‐1 Receptor Agonists

doi: 10.1016/S0140-6736(10)60406-0

Whether to utilize this type of medication is a decision individuals should discuss with their medical practitioners, taking into consideration their unique bio-individuality and needs

In compounded form, the cost difference is more manageable

They also reduce cardiovascular disease risk, as seen with semaglutide and liraglutide

[DOI] [PubMed] [Google Scholar] 86.Jin S.L., Han V.K., Simmons J.G., Towle A.C., Lauder J.M., Lund P.K

AMPLITUDE-O with efpeglenatide, the latest GLP-1 RA CVOT to report (Gerstein et al., 2021), indeed indicated a benefit on HF, with post hoc analyses showing a significant 39% relative risk reduction on HF requiring hospitalisation (HR 0.61